News / Taiwan / economic_daily
JenChem October Revenue Surges 41.2%, Ten-Month Total Beats 2025 Full-Year
Health Technology · Pharmaceuticals: Major · economic_daily · 2026-11-09
4114
JenChem's October revenue reached NT$767 million, with cumulative ten-month results already surpassing its total 2025 annual performance.
What Happened
Revenue Performance: JenChem reported October consolidated revenue of NT$767 million, a 41.2% increase year-on-year. Cumulative revenue for the first ten months reached NT$6.61 billion, up 28.5%, successfully exceeding the company's total revenue for the entire year of 2025.
New Drug Impact: Growth in the oncology segment is driven by the rapid introduction of new drugs, with lung cancer and gastrointestinal tumor treatments achieving high adoption rates in major hospitals. Additionally, urological oncology products continue to show strong clinical value and sales growth.
Product Portfolio: In the respiratory sector, the company's new nasal spray has exceeded sales expectations since its launch, gaining trust among primary care clinics. Meanwhile, new drugs for women's health and gastrointestinal conditions are expanding their reach across medical institutions.
Strategic Direction: JenChem plans to continue leveraging international partnerships and local commercialization capabilities to strengthen its core therapeutic areas. Through professional academic engagement and a diverse product portfolio, the company aims to reach its goal of becoming a major regional pharmaceutical group by 2030.